Dysanapsis and the Spirometric Response to Inhaled Bronchodilators.
作者信息
Vameghestahbanati Motahareh, Kirby Miranda, Maltais François, Jensen Dennis, Doiron Dany, Tan Wan C, Bourbeau Jean, Smith Benjamin M
机构信息
McGill University Montreal, Quebec, Canada.
Ryerson University Toronto, Ontario, Canada.
出版信息
Am J Respir Crit Care Med. 2021 Oct 15;204(8):997-1001. doi: 10.1164/rccm.202107-1574LE.
Abstract
摘要
相似文献
1
Dysanapsis and the Spirometric Response to Inhaled Bronchodilators.呼吸肌功能不全与吸入性支气管扩张剂的肺量计反应
Am J Respir Crit Care Med. 2021 Oct 15;204(8):997-1001. doi: 10.1164/rccm.202107-1574LE.
2
Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry.揭示吸入性支气管扩张剂在慢性阻塞性肺疾病中的有益作用：超越用力肺活量测定法。
J Bras Pneumol. 2019 Jun 27;45(3):e20190168. doi: 10.1590/1806-3713/e20190168.
3
Bronchodilator responsiveness in patients with chronic heart failure.慢性心力衰竭患者的支气管扩张剂反应性。
Heart Lung. 2013 May-Jun;42(3):208-14. doi: 10.1016/j.hrtlng.2012.11.007. Epub 2012 Dec 27.
4
Effects of bronchodilators on regional lung sound distribution in patients with chronic obstructive pulmonary disease.支气管扩张剂对慢性阻塞性肺疾病患者肺部区域性声音分布的影响。
Respiration. 2014;87(1):45-53. doi: 10.1159/000350228. Epub 2013 Jul 10.
5
Perseverant, non-indicated treatment of obese patients for obstructive lung disease.坚持对非肥胖阻塞性肺疾病患者进行治疗。
BMC Pulm Med. 2013 Nov 22;13:68. doi: 10.1186/1471-2466-13-68.
6
Bronchodilator reversibility in COPD.COPD 的支气管扩张剂可逆性。
Chest. 2011 Oct;140(4):1055-1063. doi: 10.1378/chest.10-2974.
7
Bronchodilator response of advanced lung function parameters depending on COPD severity.根据慢性阻塞性肺疾病（COPD）严重程度，晚期肺功能参数的支气管扩张剂反应。
Int J Chron Obstruct Pulmon Dis. 2016 Nov 25;11:2939-2950. doi: 10.2147/COPD.S111573. eCollection 2016.
8
Regional lung response to bronchodilator reversibility testing determined by electrical impedance tomography in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中通过电阻抗断层扫描测定的区域肺对支气管扩张剂可逆性测试的反应。
Am J Physiol Lung Cell Mol Physiol. 2016 Jul 1;311(1):L8-L19. doi: 10.1152/ajplung.00463.2015. Epub 2016 May 17.
9
Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?阻塞性肺疾病中吸入用肾上腺素能药物和抗胆碱能药物：它们能增强黏液纤毛清除功能吗？
Respir Care. 2007 Sep;52(9):1159-73; discussion 1173-5.
10
[Importance of the distal airway in COPD].[远端气道在慢性阻塞性肺疾病中的重要性]
Arch Bronconeumol. 2011 Apr;47 Suppl 2:32-7. doi: 10.1016/S0300-2896(11)70019-9.
引用本文的文献
1
Dysanapsis as a Determinant of Lung Function in Development and Disease.发育及疾病中肺功能的决定因素——发育不全
Am J Respir Crit Care Med. 2023 Nov 1;208(9):956-963. doi: 10.1164/rccm.202306-1120PP.
2
A computed tomography imaging-based subject-specific whole-lung deposition model.基于计算机断层扫描成像的个体全肺沉积模型。
Eur J Pharm Sci. 2022 Oct 1;177:106272. doi: 10.1016/j.ejps.2022.106272. Epub 2022 Jul 29.
3
Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan.慢性阻塞性肺疾病的发病机制：了解基因-环境相互作用在整个生命周期中的贡献。
Lancet Respir Med. 2022 May;10(5):512-524. doi: 10.1016/S2213-2600(21)00555-5. Epub 2022 Apr 12.
本文引用的文献
1
Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry.ERS 官方技术标准：欧洲血统个体静态肺容量的全球肺功能倡议参考值。
Eur Respir J. 2021 Mar 11;57(3). doi: 10.1183/13993003.00289-2020. Print 2021 Mar.
2
Central Airway Tree Dysanapsis Extends to the Peripheral Airways.中央气道树发育不全延伸至外周气道。
Am J Respir Crit Care Med. 2021 Feb 1;203(3):378-381. doi: 10.1164/rccm.202007-3025LE.
3
Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults.大龄人群中发育不良与慢性阻塞性肺疾病的相关性研究。
JAMA. 2020 Jun 9;323(22):2268-2280. doi: 10.1001/jama.2020.6918.
4
Predicting treatable traits for long-acting bronchodilators in patients with stable COPD.预测稳定期慢性阻塞性肺疾病患者长效支气管扩张剂的可治疗特征。
Int J Chron Obstruct Pulmon Dis. 2017 Dec 12;12:3557-3565. doi: 10.2147/COPD.S151909. eCollection 2017.
5
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.慢性阻塞性肺疾病全球策略：诊断、管理与预防 2017 年报告。GOLD 执行摘要。
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.
6
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.慢性阻塞性肺疾病的长效吸入疗法（β受体激动剂、抗胆碱能药物和类固醇）：一项网状荟萃分析。
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.
7
Predictors of response to tiotropium versus salmeterol in asthmatic adults.噻托溴铵与沙美特罗治疗哮喘成人患者的疗效预测因子。
J Allergy Clin Immunol. 2013 Nov;132(5):1068-1074.e1. doi: 10.1016/j.jaci.2013.08.003. Epub 2013 Sep 29.
8
Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the need for longitudinal observational studies in COPD.加拿大队列阻塞性肺疾病研究（CanCOLD）：满足 COPD 纵向观察研究的需求。
COPD. 2014 Apr;11(2):125-32. doi: 10.3109/15412555.2012.665520. Epub 2012 Mar 20.
9
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.长效β2受体激动剂与相同剂量吸入性糖皮质激素联合应用于成人及儿童慢性哮喘的疗效比较
Cochrane Database Syst Rev. 2010 May 12(5):CD005535. doi: 10.1002/14651858.CD005535.pub2.
10
International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.慢性阻塞性肺疾病患病率的国际差异（BOLD研究）：一项基于人群的患病率研究。
Lancet. 2007 Sep 1;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4.
Zotero 插件